CalciMedica, Inc. (CALC)

Insider Trading Filed: 2026-04-07

The reporting person, A. Rachel Leheny, is the Chief Executive Officer and a 10% owner of CalciMedica, Inc.
Leheny acquired 148,482 stock options on April 5, 2025, with a strike price of $0.585 and an expiration date of April 4, 2036.
The options will vest in equal monthly installments over a four-year period starting April 1, 2026, subject to the filing of the company's registration statement on Form S-8.

Insider Trading Filed: 2026-04-07

The reporting person, Kenneth A. Stauderman, acquired 65,124 employee stock options with an exercise price of $0.585 on 2025-04-05, vesting over a four-year period starting 2026-04-01.
The options granted to the Chief Scientific Officer indicate continued confidence in the company's long-term growth prospects.
The transaction is a routine insider option grant and does not signal any significant changes in the company's operations or financial condition.

Insider Trading Filed: 2026-04-07

Michael J. Dunn, the President and COO of CalciMedica, Inc. (CALC), acquired 65,124 stock options with a strike price of $0.585 and a four-year vesting period, indicating his confidence in the company's future performance.
The stock options were granted on April 5, 2025, and the vesting is contingent on the filing of the company's registration statement on Form S-8, which could provide additional shares for the equity incentive plan.
Insider buying, such as this option grant, can be a positive signal for investors, as it suggests management believes the company's stock is undervalued and has potential for growth.

Insider Trading Filed: 2026-04-07

Eric W. Roberts, the Chief Business Officer and a 10% owner of CalciMedica, Inc. (CALC), exercised 83,358 stock options at $0.585 per share on April 5, 2026, indicating his confidence in the company's future prospects.
The stock options granted to Eric W. Roberts vest over a four-year period, subject to the filing of a registration statement on Form S-8 covering the shares added to the company's equity incentive plan on January 1, 2026, suggesting a long-term commitment to the company.
The exercise of stock options by a key insider like the Chief Business Officer and a significant shareholder could be a positive signal for investors, as it may indicate management's belief in the company's growth potential.

Insider Trading Filed: 2026-04-07

Insider Sudarshan Hebbar, the Chief Medical Officer, acquired 91,173 stock options of CalciMedica, Inc. (CALC) at an exercise price of $0.585 per share.
The options vest over a four-year period, with the first shares vesting on April 4, 2036, subject to the filing of a registration statement on Form S-8 covering the additional shares authorized under the company's equity incentive plan.
This transaction suggests Hebbar's confidence in the company's future prospects and aligns his interests with those of other shareholders.

Insider Trading Filed: 2026-04-07

Stephen Bardin, the Chief Financial Officer of CalciMedica, Inc., exercised 67,728 stock options with an exercise price of $0.585 per share, indicating his confidence in the company's future prospects.
The vesting of the stock options is subject to the filing of the company's registration statement on Form S-8, which suggests an upcoming equity incentive plan update or expansion.
Insider transactions, such as this option exercise, can provide insight into management's view of the company's valuation and growth potential.

Current Report Filed: 2026-03-18

CalciMedica, Inc. has received two notices from Nasdaq indicating non-compliance with listing requirements related to minimum market value of listed securities ($35 million) and minimum bid price ($1 per share).
The company has 180 days to regain compliance with these requirements, which could include conducting a reverse stock split or taking other actions.
Failure to regain compliance within the allotted time could result in the company's stock being delisted from the Nasdaq Capital Market.

Current Report Filed: 2026-03-03

CalciMedica, Inc. reported its financial results for the full year 2025, showing a slight decline in revenue compared to the previous year.
The company did not provide any forward-looking guidance in its earnings release, which could indicate uncertainty about its future prospects.
There were no notable leadership changes or material agreements announced in this 8-K filing.

Annual Report Filed: 2026-03-03

CalciMedica, Inc. (CALC) filed its 10-K report for the fiscal year 2025, providing insight into the company's financial performance and key business developments.
The filing indicates that CalciMedica is primarily focused on research and development (R&D) activities, with R&D expenses comprising a significant portion of its total expenses.
The company appears to have utilized various financing activities, including a private placement, an at-the-market offering, and a loan agreement, to fund its operations and R&D efforts.

Current Report Filed: 2026-01-28

CalciMedica, Inc. has discontinued its Phase 2 KOURAGE clinical trial evaluating Auxora in patients with acute kidney injury and acute hypoxemic respiratory failure, following a recommendation from the Independent Data Monitoring Committee.
The decision to discontinue the trial was due to a safety concern identified during the interim data review, though there were no deaths related to the study drug.
The company plans to perform a comprehensive review of the unblinded clinical data to assess the impact of baseline characteristics, disease severity, and other factors on patient outcomes, which could inform future clinical evaluation of Auxora.

Current Report Filed: 2026-01-28

CalciMedica has discontinued its Phase 2 KOURAGE clinical trial based on a recommendation from the Independent Data Monitoring Committee, indicating potential issues with the trial or product candidate.
The company has updated its financial guidance, with its existing cash, cash equivalents, and short-term investments now expected to fund operations into the fourth quarter of 2026, earlier than the previously disclosed second half of 2026.
The discontinuation of the KOURAGE trial and resulting reduction in planned operating expenses could have a significant impact on the company's financial position and future development plans.

Important Information